EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Phaos Technology Holdings (POAS) fair value: what the stock is really worth

As of Sep 22, 2026: fair value of Phaos Technology Holdings $0.20, price $0.17, upside +20.0%, quality 14 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN KYG7049C1042

PT Phaos Technology Holdings logo Thin data Sep 24, 2026

Phaos Technology Holdings

POAS · US

SpeculativeUpside exists, but weak quality makes the signal speculative.

Fair value $0.2040 · Undervalued (+20%)
!Quality 14/100
!Weak Growth (revenue 3y −41.2 %/yr)
!Low debt · negative free cash flow
!Trails peers (3/8)
!Narrow moat 8/100
!Evidence only low, so the estimate is less certain

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$6.60 $0.1600 Fair Value $0.2040 Nov 2025 Sep 2026

White line = price, green steps = our fair value per fiscal year. As of Sep 24, 2026.

How to read this chart

10‑month range $0.1600 – $6.60 · fair‑value band $0.1360 – $0.2550 · the $0.1700 price screens below the $0.2040 fair value. As of Sep 24, 2026.

Follow Phaos Technology in your weekly email

Every Wednesday you see whether Phaos Technology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Phaos Technology Holdings (Cayman) Limited, through its subsidiary, Phaos Technology Pte. Ltd., engages in the manufacturing and commercialization of advanced microscopy-related solutions, technologies, and products in Singapore.

Show more

Phaos Technology Holdings (Cayman) Limited, through its subsidiary, Phaos Technology Pte. Ltd., engages in the manufacturing and commercialization of advanced microscopy-related solutions, technologies, and products in Singapore. The company offers Optonano that enables users to view live and still images for construction of high-quality image of larger sample areas; PT-Industrial for use in material study, failure analysis, simple measuring, quality control, inspection, and manufacturing; and PT-Metrology, which provides dimensional measurements with a single key operation. It also provides PT-Biology to create specialized images needed in the biomedical sector; PT-Stereo, a stereo microscope designed to provide clear magnified stereoscopic images that amplify solid or thick samples; and PT-Zoom that offers three-dimensional magnified view of samples to enhance visualization. In addition, the company offers software. The company serves manufacturing companies; biomedical service providers; and research and development institutions. The company was founded in 2017 and is based in Singapore.

Stock analysis

Phaos Technology Holdings (POAS) currently trades at $0.1700, while our model-based Fair Value estimate is $0.2040, implying the stock looks roughly 16.7% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 92/100, which puts the evidence level at low.

Scenario range: $0.1360 (bear) to $0.2550 (bull), the price of $0.1700 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 14/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Phaos Technology Holdings reported revenue of 132K SGD in FY2026 versus 651K SGD in FY2023, a compound −41.2%/yr. Reported net income was −6.2M SGD in FY2026.

Key figures

Market cap $5.2M · P/S ratio 39.2 · EPS (TTM) $−0.3800 · Return on equity −369% · Return on assets (EBIT) −141% · Operating margin −10,748% · Revenue (TTM) 132K SGD · Revenue growth (YoY) −57.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 20%, POAS screens cheaper than that median.

Fair Value models

Bear $0.1360 Fair Value $0.2040 Bull $0.2550
Model Each model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence Evidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.1600 $0.2200 $0.3200 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.1600 $0.2200 $0.3200 54

Open the full fair value analysis →

Notify me when POAS reaches fair value

Put POAS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 14/100

Of which business quality 21 · Market factors (momentum, volatility) 0

Profitability 0
Margins and returns on capital today
Quality Growth 23
Are margins and returns improving?
Cashflow 28
Earnings quality: real cash, not paper profit
Fin. Strength 59
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 2
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality Growth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−21.2%
Revenue growth 3 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−41.2%
Profit margin (trend) Operating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−313.8% (2023) → −4,771.2% (2026)
What shareholders gained per year We only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Watch POAS, get fair value alerts →

Compare Phaos Technology Holdings with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 361 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 21 · Bottom 25%
Fair Value upside +20% · Top 25%
Profitability
Return on assets −92% · Bottom 25%
Growth and dividend
Revenue growth −58% · Bottom 25%
Balance sheet
Debt / equity 0.00× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.98× · Cheaper than median
P/S (TTM) 39.20× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)60 · sector 3
FUTURE (revenue growth)0 · sector 30
PAST (return on equity)0 · sector 5
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 38

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $103.69 $74.79 −28%
Stryker Corporation SYK $275.09 $302.60 +10%
Medtronic plc MDT $90.77 $65.57 −28%
Boston Scientific Corporation BSX $44.92 $49.41 +10%
Edwards Lifesciences Corporation EW $88.78 $82.04 −8%
Siemens Healthineers AG SHL €37.43 €35.22 −6%
DexCom, Inc DXCM $89.53 $98.48 +10%
GE HealthCare Technologies Inc GEHC $66.27 $69.62 +5%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥156.68 ¥172.35 +10%
Koninklijke Philips N.V PHIA €21.85 €15.32 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Phaos Technology Holdings Fair Value". https://www.fairvalue-calculator.com/stock/POAS

Frequently asked questions

Is Phaos Technology Holdings (POAS) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.2040 versus a price of $0.1700, about +20% upside (undervalued).
What is the fair value of POAS?
Our model-based fair value for Phaos Technology Holdings is $0.2040 (as of Sep 24, 2026), built from audited fundamentals. The current price: $0.1700.
What is the quality score of POAS?
Phaos Technology Holdings has a Quality Score of 14/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Phaos Technology Holdings (POAS)?
Our model-based price target is the fair value of $0.2040 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $0.1360, optimistic scenario $0.2550. It is a calculation from audited fundamentals, not an analyst target.
What is the Phaos Technology Holdings stock forecast for 2026?
Our models put fair value at $0.2040, about +20% upside versus a price of $0.1700 (undervalued). Cautious scenario $0.1360, optimistic scenario $0.2550. The calculation is refreshed regularly with new filings.
What is the revenue of Phaos Technology Holdings (POAS)?
Phaos Technology Holdings reported trailing-twelve-month revenue of about 192K SGD (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Phaos Technology Holdings (POAS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Phaos Technology Holdings it is $0.2040 per share (as of Sep 24, 2026), against a price of $0.1700. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Phaos Technology Holdings stock overvalued or undervalued in 2026?
As of Sep 24, 2026, POAS trades below its calculated fair value: price $0.1700, fair value $0.2040, a gap of about +20% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of POAS?
No. The price is what the market pays today ($0.1700); the fair value is what the company's own numbers justify ($0.2040). For Phaos Technology Holdings the two are $0.0340 per share apart. That gap is exactly why we show both numbers side by side.
How much is Phaos Technology Holdings worth?
The market values Phaos Technology Holdings at about $5.2M (market capitalisation, as of Sep 24, 2026). Per share that is $0.1700; our models calculate a fair value of $0.2040 per share.
What do the bullish and bearish scenarios say about POAS?
Our models span a range for Phaos Technology Holdings: cautious scenario $0.1360, base $0.2040, optimistic $0.2550 per share (as of Sep 24, 2026, price $0.1700). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Phaos Technology Holdings (POAS)?
Balance-sheet figures for Phaos Technology Holdings (as of Sep 24, 2026): return on equity −369.0%, debt of 0.00 per unit of equity. They feed the Quality Score of 14/100, which measures business quality independently of the share price.
Which stocks are comparable to Phaos Technology Holdings?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Phaos Technology Holdings stock attractive at the current price?
The data as of Sep 24, 2026: price $0.1700, calculated fair value $0.2040 (+20%), Quality Score 14/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of POAS calculated?
We run Phaos Technology Holdings through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.2040, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Phaos Technology Holdings currently trades 20 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Phaos Technology Holdings (POAS)?
The closing price on Sep 22, 2026 was $0.1700. Our model-based fair value is $0.2040, about +20% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Phaos Technology Holdings right now?
A fairly wide model range ($0.1360 to $0.2550) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Phaos Technology Holdings

How large is the market capitalisation of Phaos Technology Holdings (POAS)?
The market capitalisation of Phaos Technology Holdings is $5.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Phaos Technology Holdings (POAS)?
The price-to-sales ratio of Phaos Technology Holdings is 39.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Phaos Technology Holdings (POAS)?
Earnings per share at Phaos Technology Holdings are $−0.3800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Phaos Technology Holdings (POAS)?
The return on equity (ROE) of Phaos Technology Holdings is −369% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Phaos Technology Holdings (POAS)?
On an EBIT basis the return on assets of Phaos Technology Holdings is −141% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Phaos Technology Holdings (POAS)?
The operating margin of Phaos Technology Holdings is −10,748% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Phaos Technology Holdings (POAS)?
Revenue at Phaos Technology Holdings is growing −57.5% versus a year earlier (3y avg −41.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Phaos Technology Holdings (POAS) generate?
The free cash flow of Phaos Technology Holdings is −10.9M SGD (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Phaos Technology Holdings (POAS) hold?
Phaos Technology Holdings holds more cash than debt, 311K SGD net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Phaos Technology Holdings in the live analysis

One click puts Phaos Technology Holdings on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.